{"id":45640,"date":"2022-06-29T15:01:58","date_gmt":"2022-06-29T13:01:58","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\/"},"modified":"2022-06-29T15:01:58","modified_gmt":"2022-06-29T13:01:58","slug":"reflow-medical-completes-deeper-limus-clinical-trial-enrollment","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\/","title":{"rendered":"Reflow Medical Completes DEEPER LIMUS Clinical Trial Enrollment"},"content":{"rendered":"
\n

SAN CLEMENTE, Calif.–(BUSINESS WIRE)–#CLIFighters<\/a>—Reflow Medical, Inc.<\/a>, a California-based medical device company, has completed enrollment in the DEEPER LIMUS clinical trial (NCT04162418) to evaluate the Temporary Spur Stent System, a patented device designed to treat long, diffuse and severely calcified infrapopliteal disease. The system allows for uniform expansion of the stent to maximize lumen diameter and may reduce acute vessel recoil and dissections.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nEngineered to fulfill an unmet clinical need in treating patients suffering from Critical Limb Ischemia (CLI), the Temporary Spur Stent System<\/a> consists of a unique, retrievable nitinol stent system with radially expandable spikes or \u201cspurs\u201d designed to create channels for increased uptake of antiproliferative drugs (\u201climus\u201d based) into the vessel wall. The system is then recaptured and removed, without leaving anything behind.\n<\/p>\n

\n\u201cWe were impressed from the start with the acute luminal gain we were able to achieve,\u201d says Marianne Brodmann, MD, who is a Professor and Vascular Specialist at the Medical University of Graz, Austria, and the Principal Investigator for the study. \u201cIt\u2019s eye-opening, how the vessel responds. The device is also intuitive and easy to use.\u201d\n<\/p>\n

\nTeo Jimenez, Reflow Medical\u2019s Senior Vice President of Research and Development said, \u201cFinishing enrollment in this study continues to highlight the versatility and safety of the Spur device with multiple drug-coated platforms.\u201d\n<\/p>\n

\n\u201cOn behalf of the team here at Reflow, we offer sincere thanks and gratitude for the partnership with Professor Brodmann and her team,\u201d commented Isa Rizk, CEO and Co-founder of Reflow Medical. \u201cTheir ability to perform this study during a global pandemic and achieve this milestone shows their commitment and dedication to advancing technologies in the CLI space.\u201d\n<\/p>\n

\nAbout Reflow Medical, Inc.<\/b>\n<\/p>\n

\nReflow Medical, Inc. is a private company focused on empowering physicians through the design and development of innovative and effective technologies for cardiovascular disease. Reflow is currently developing a family of products to treat cardiovascular disease.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nJennifer Carlyle
\n
jcarlyle@reflowmedical.com<\/a>
949-481-0399\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN CLEMENTE, Calif.–(BUSINESS WIRE)–#CLIFighters—Reflow Medical, Inc., a California-based medical device company, has completed enrollment in the DEEPER LIMUS clinical trial (NCT04162418) to evaluate the Temporary Spur Stent System, a patented device designed to treat long, diffuse and severely calcified infrapopliteal disease. The system allows for uniform expansion of the stent to maximize lumen diameter and … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45640","6":"format-standard","7":"category-industry"},"yoast_head":"\nReflow Medical Completes DEEPER LIMUS Clinical Trial Enrollment - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Reflow Medical Completes DEEPER LIMUS Clinical Trial Enrollment - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN CLEMENTE, Calif.–(BUSINESS WIRE)–#CLIFighters—Reflow Medical, Inc., a California-based medical device company, has completed enrollment in the DEEPER LIMUS clinical trial (NCT04162418) to evaluate the Temporary Spur Stent System, a patented device designed to treat long, diffuse and severely calcified infrapopliteal disease. The system allows for uniform expansion of the stent to maximize lumen diameter and ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-29T13:01:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220628006094\/en\/1499713\/21\/Spur_render.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Reflow Medical Completes DEEPER LIMUS Clinical Trial Enrollment\",\"datePublished\":\"2022-06-29T13:01:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\\\/\"},\"wordCount\":332,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220628006094\\\/en\\\/1499713\\\/21\\\/Spur_render.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\\\/\",\"name\":\"Reflow Medical Completes DEEPER LIMUS Clinical Trial Enrollment - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220628006094\\\/en\\\/1499713\\\/21\\\/Spur_render.jpg\",\"datePublished\":\"2022-06-29T13:01:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220628006094\\\/en\\\/1499713\\\/21\\\/Spur_render.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220628006094\\\/en\\\/1499713\\\/21\\\/Spur_render.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Reflow Medical Completes DEEPER LIMUS Clinical Trial Enrollment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Reflow Medical Completes DEEPER LIMUS Clinical Trial Enrollment - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\/","og_locale":"en_US","og_type":"article","og_title":"Reflow Medical Completes DEEPER LIMUS Clinical Trial Enrollment - Pharma Trend","og_description":"SAN CLEMENTE, Calif.–(BUSINESS WIRE)–#CLIFighters—Reflow Medical, Inc., a California-based medical device company, has completed enrollment in the DEEPER LIMUS clinical trial (NCT04162418) to evaluate the Temporary Spur Stent System, a patented device designed to treat long, diffuse and severely calcified infrapopliteal disease. The system allows for uniform expansion of the stent to maximize lumen diameter and ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-29T13:01:58+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220628006094\/en\/1499713\/21\/Spur_render.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Reflow Medical Completes DEEPER LIMUS Clinical Trial Enrollment","datePublished":"2022-06-29T13:01:58+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\/"},"wordCount":332,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220628006094\/en\/1499713\/21\/Spur_render.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\/","url":"https:\/\/pharma-trend.com\/en\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\/","name":"Reflow Medical Completes DEEPER LIMUS Clinical Trial Enrollment - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220628006094\/en\/1499713\/21\/Spur_render.jpg","datePublished":"2022-06-29T13:01:58+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220628006094\/en\/1499713\/21\/Spur_render.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220628006094\/en\/1499713\/21\/Spur_render.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/reflow-medical-completes-deeper-limus-clinical-trial-enrollment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Reflow Medical Completes DEEPER LIMUS Clinical Trial Enrollment"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45640","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45640"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45640\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45640"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45640"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45640"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}